Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
IO Biotech Logo
IO Biotech Growth Score
42
CB Rank
9288
Heat Score
55
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
Founded
obfuscation
PublicPost-IPO Equity Copenhagen, Hovedstaden, Denmark51-100 www.iobiotech.com/
Biotechnology
Health Care
Therapeutics
Overview

IO Biotech
Total Funding
obfuscation
Growth Score
42
Heat Score
55

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score42
5 pts
in past quarter
Heat Score 55
-12 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About IO Biotech

CB Rank
9288
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
Founded
obfuscation
PublicPost-IPO Equity Copenhagen, Hovedstaden, Denmark51-100 www.iobiotech.com/
Biotechnology
Health Care
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name IO Biotech ApS
Operating Status Active
Stock Symbol  NASDAQ:IOBT
Company Type For Profit
Founders  Anders Ljungqvist, Inge Svane, Mads Andersen, Mai-Britt Zocca, Per Straten
About the Company

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven

track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

Phone Number +45 452- 194-7856
Contact Email mz@iobiotech.com
Predictions & Insights

Growth Insight

See this Growth Insight
IO Biotech is
Lorem
 to be growing
Top Contributing Factors
Financial Decline

Products & Services

Cylembio
An investigational off-the-shelf therapeutic cancer vaccine targeting IDO1 and PD-L1 to modulate the tumor microenvironment and enhance anti-tumor immune response.
IO170
A therapeutic cancer vaccine targeting Transforming Growth Factor beta (TGF-β) to modulate the tumor microenvironment and stimulate anti-tumor immune responses.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - IO Biotech Logo
Post-IPO Equity - IO Biotech
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
European Investment Bank Logo
European Investment Bank
Yes
Post-IPO Debt - IO Biotech Logo
Post-IPO Debt - IO Biotech
—
European Investment Bank Logo
European Investment Bank
Yes
Post-IPO Debt - IO Biotech Logo
Post-IPO Debt - IO Biotech
—
European Investment Bank Logo
European Investment Bank
Yes
Post-IPO Debt - IO Biotech Logo
Post-IPO Debt - IO Biotech
—
European Investment Bank Logo
European Investment Bank
Yes
Post-IPO Debt - IO Biotech Logo
Post-IPO Debt - IO Biotech
—
European Investment Bank Logo
European Investment Bank
Yes
Post-IPO Debt - IO Biotech Logo
Post-IPO Debt - IO Biotech
—
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 8 Board Members and Advisors 10 Contacts 41

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,623
14.14%
 in past month

IT Spend

$3.7MThis year, IO Biotech is projected to spend $3.7M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Internet Access Logo
Internet Access
99
Design Software Logo
Design Software
96
NVIDIA RTX Logo
NVIDIA RTX
93

Actively Used Products

25IO Biotech uses 25 technology products and services including HTML5, jQuery, and  Modernizr, according to G2 Stack.

Active Website Tech Count

31IO Biotech is actively using 31 technologies for its website, according to BuiltWith. These include Apple Mobile Web Clips Icon, Google Tag Manager, and  Content Delivery Network.

Total IP

56The intellectual property of IO Biotech includes 33 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, IO Biotech has registered 23 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is IO Biotech's headquarters? IO Biotech is located in Copenhagen, Hovedstaden, Denmark.Who invested in IO Biotech? IO Biotech has 17 investors including European Investment Bank and  HBM Healthcare Investments.When was the last funding round for IO Biotech? IO Biotech closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are IO Biotech's competitors? Alternatives and possible competitors to IO Biotech may include Avenzo Therapeutics, Calidi Biotherapeutics, and  Canton Strategic Holdings.How much funding has IO Biotech raised to date? IO Biotech has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(9fd75b2 1)
|